AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8369005
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release diltiazem (360 mg)
Trial: 8369005
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release diltiazem (60 mg, thrice a day)
Trial: 31479032
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate 3, 6.25, 12.5, or 25 mg weekly intramuscular injections
Trial: 29096836
Drug: Weekly lipoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly lipoprotein apheresis by cascade plasma filtration (CPF) plus atorvastatin
Trial: 21444866
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy and surgery (CS group; n = 113)
Trial: 18649004
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg (treatment group)
Trial: 15112937
Drug: Promising medications
RxNorm normalized name: pramoxine
DrugBank: Pramocaine (DB09345)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promising medications
Trial: 16350386
Drug: Low coronary
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low coronary perfusion pressure at 50 mmHg for 90 seconds followed by high at 80 mmHg for 90 seconds (group L‐H)
Trial: 16350386
Drug: High coronary
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High coronary perfusion pressure at 80 mmHg for 90 seconds followed by low at 50 mmHg for 90 seconds (group H‐L)
Trial: 12135589
Drug: Dexamethasone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (24 mg/day) for 4 days and atracurium (0.3-0.6 mg/kg/h) for 2.8 days (group C)
Trial: 12135589
Drug: Dexamethasone (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (24 mg/day) for 4 days (group B)
Trial: 7631051
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and sulindac
Trial: 7631051
Drug: Certain antihypertensive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Certain antihypertensive drugs (Ca2+ channel blockers, centrally acting alpha agonists, diuretics)
Trial: 7631051
Drug: Thromboxane synthase
RxNorm normalized name: Thromboxane synthase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thromboxane synthase inhibitors and selective inhibitors of PGH synthase-2
Trial: 2067035
Drug: Bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus therapy with doxorubicin (60 mg/m2) and dacarbazine (750 mg/m2) intravenously on day 1
Trial: 2067035
Drug: Infusional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusional therapy with doxorubicin (60 mg/m2) and dacarbazine (750 mg/m2) delivered by continuous intravenous infusion for 96 hours on days 1-4
Trial: 6223483
Drug: Previous oral
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous oral contraception use
Trial: 21079521
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with paclitaxel and carboplatin (PCB)
Trial: 20467615
Drug: 7‐mm‐long NanoTite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐mm‐long NanoTite External Hex implants (Biomet 3i)
Trial: 20467615
Drug: 10‐mm or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mm or longer implants placed in vertically augmented bone
Trial: 20467615
Drug: Vertical bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vertical bone augmentation
Trial: 20467615
Drug: 7‐mm short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7‐mm short implants
Trial: 17588704
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 over 30 min on Days 1 and 8 of a 21-day cycle (standard arm, N=33)
Trial: 17588704
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 at a fixed dose rate of 10 mg/m2/min on Days 1 and 8 of a 21-day cycle (FDR arm, N=31)
Trial: 15564706
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blocker (ARB) for 1 month
Trial: 15564706
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blocker (ARB) for at least 6 months
Trial: 15564706
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-hypertensive drugs other than ARB)
Trial: 9388086
Drug: Control (Inpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Inpatient treatment)
Trial: 7999471
Drug: Ideal combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ideal combination oral contraceptive
Trial: 7999471
Drug: LHRH agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH agonist oophorectomy
Trial: 7999471
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of estrogen metabolism
Trial: 3297938
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pirenzepine tablets
Trial: 27881559
Drug: CSL112 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (2 g apoA‐I per dose)
Trial: 27881559
Drug: High-dose CSL112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CSL112 (6 g apoA‐I per dose)
Trial: 27881559
Drug: CSL112 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (2 g apoA‐I per dose) and High-dose CSL112 (6 g apoA‐I per dose)
Trial: 22554598
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg prasugrel
Trial: 22554598
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg prasugrel
Trial: 20808309
Drug: ADI-PEG 20
RxNorm normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADI-PEG 20 at doses of 160 or 320 IU m(‐2)
Trial: 16049208
Drug: Echinacea angustifolia
RxNorm normalized name: Echinacea Angustifolia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea angustifolia extracts (three preparations: supercritical carbon dioxide, 60% ethanol, 20% ethanol)
Trial: 12823436
Drug: 5% vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% vitamin C cream
Trial: 1523350
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg pm
Trial: 1523350
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg bi
Trial: 6592034
Drug: Multiagent induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiagent induction and single-agent maintenance chemotherapy with randomization to an immunotherapy arm.
Trial: 6592034
Drug: Elective surgical
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective surgical splenectomy performed for 42 patients at the completion of 3 months of induction therapy.
Trial: 30279015
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg twice daily
Trial: 24284444
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g · kg(‐1) · d(‐1) protein (2 × RDA)
Trial: 24284444
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g · kg(‐1) · d(‐1) protein (3 × RDA)
Trial: 24284444
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g · kg(‐1) · d(‐1) protein (RDA)
Trial: 17389553
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid 2 mg/kg/h
Trial: 17389553
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid 4 mg/kg/h
Trial: 17389553
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid 6 mg/kg/h
Trial: 17389553
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid 8 mg/kg/h
Trial: 17389553
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid 10 mg/kg/h
Trial: 17389553
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid 12 mg/kg/h
Trial: 17389553
Drug: Arundic acid
RxNorm normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arundic acid (all doses)
Trial: 26222126
Drug: TAK-085 4
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-085 4 g/day
Trial: 26222126
Drug: TAK-085 2
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-085 2 g/day
Trial: 21502572
Drug: Revacept 10
RxNorm normalized name: Revacept
DrugBank: PR-15 (DB06037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revacept 10 mg
Trial: 21502572
Drug: Revacept 20
RxNorm normalized name: Revacept
DrugBank: PR-15 (DB06037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revacept 20 mg
Trial: 21502572
Drug: Revacept 40
RxNorm normalized name: Revacept
DrugBank: PR-15 (DB06037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revacept 40 mg
Trial: 16332417
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 20 microg ethinyl estradiol plus 0.15 mg desogestrel
Trial: 16332417
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 0.100 mg levonorgestrel
Trial: 16332417
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 0.75 mg of gestodene
Trial: 12908665
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation 'atypical' antipsychotics
Trial: 11103221
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml grape-skin extract in water (1 mg extract/ml) at each of three daily meals (31.3 mg total phenolics, including 9.0 mg catechin)
Trial: 27188329
Drug: Traditional DMARD
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional DMARD therapy
Trial: 22252346
Drug: 60% feed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% feed restriction on d 4, 5, and 6 plus 1,500 mg/kg of quercetin (FR60Q)
Trial: 18033957
Drug: Ticlopidine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 200 mg once daily
Trial: 12105164
Drug: EP-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-guided therapy with ICD
Trial: 12105164
Drug: EP-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-guided therapy without ICD
Trial: 31559966
Drug: T14 (triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T14 (triple therapy for 14 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, all given twice daily)
Trial: 31559966
Drug: C10 (concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C10 (concomitant therapy for 10 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Trial: 31559966
Drug: BQ10 (bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ10 (bismuth quadruple therapy for 10 days; bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Trial: 15014297
Drug: Ibuprofen (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (10 mg/kg every 6 h until 36 h after defervescence)
Trial: 15014297
Drug: Paracetamol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (12 mg/kg every 6 h until 36 h after defervescence)
Trial: 11716884
Drug: Adjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemoradiotherapy (20 Gy in ten daily fractions over 2 weeks with 500 mg/m(2) fluorouracil intravenously on days 1‐3, repeated after 2 weeks)
Trial: 11716884
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (intravenous fluorouracil 425 mg/m(2) and folinic acid 20 mg/m(2) daily for 5 days, monthly for 6 months)
Trial: 8175136
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (14 mg/kg/body wt/day)
Trial: 3330593
Drug: Enoxacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (single 400 mg dose)
Trial: 3330593
Drug: Trimethoprim (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (single 600 mg dose)
Trial: 22994054
Drug: Compound Xuanju
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Xuanju Capsule plus tamoxifen citrate
Trial: 20194828
Drug: Sertraline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline treatment for 12 weeks, titrated by clinical response
Trial: 15787865
Drug: Oral cetirizine
RxNorm normalized name: cetirizine Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cetirizine 0.25 mg/kg twice daily for 18 months
Trial: 2258894
Drug: co-dergocrine mesilate/nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-dergocrine mesilate/nifedipine (4 mg/40 mg once daily)
Trial: 2258894
Drug: mefruside/nifedipine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mefruside/nifedipine (25 mg/40 mg once daily)
Trial: 7422046
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific preparation
Trial: 31303184
Drug: Micronutrient powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient powder (MNP) with 6 mg Fe plus fourteen micronutrients
Trial: 21625270
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg once daily for 6 months
Trial: 19076190
Drug: Ultraviolet B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultraviolet B light therapy (UVB)
Trial: 19076190
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PDL and UVB
Trial: 14963464
Drug: apomorphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apomorphine 2 mg
Trial: 2590271
Drug: Magnesium-aluminum-antacid (Mucal-Gel)
RxNorm normalized name: Magnesium Aluminum Silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-aluminum-antacid (Mucal-Gel)
Trial: 31343761
Drug: 5 protocolized
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 protocolized telephone calls added to usual treatment
Trial: 30848033
Drug: LY+TT223 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY+TT223 (3 mg)
Trial: 30848033
Drug: LY+TT223 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY+TT223 (2 mg)
Trial: 25634940
Drug: Exercise specialist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise specialist led lifestyle program targeting increased daily walking with individualized daily pedometer step goals for the first 3 months and brisk walking speed, along with substitution of low‐relative to high‐glycemic index foods over the next 3 months.
Trial: 24034079
Drug: 14-day infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day infusion of NBP followed by NBP capsule
Trial: 24034079
Drug: 14-day infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day infusion of NBP followed by aspirin
Trial: 24034079
Drug: 14-day infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day infusion of ozagrel followed by aspirin
Trial: 21516550
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for MA dependence
Trial: 19079997
Drug: Prophylactic portal
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic portal vein chemotherapy (PVC) after operation
Trial: 16623676
Drug: Increased protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased protein nitrogen appearance (0.2 g/kg/day)
Trial: 16623676
Drug: Increased calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased calcium carbonate use (2 g/day)
Trial: 12767316
Drug: Flickering light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flickering light stimulation at 100 mg/dl blood glucose
Trial: 12767316
Drug: Flickering light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flickering light stimulation at 300 mg/dl blood glucose
Trial: 1442596
Drug: High dosages
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosages of diuretics
Trial: 1442596
Drug: Lower dosages
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dosages of diuretics
Trial: 1442596
Drug: Potassium-sparing antihypertensive
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-sparing antihypertensive regimens
Trial: 3914582
Drug: Mg lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg lactate for 16 weeks
Trial: 3914582
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for the first 8 weeks, followed by Mg lactate for the next 8 weeks
Trial: 27206947
Drug: Combination Ezetimibe/Simvastatin/Niacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Ezetimibe/Simvastatin/Niacin (E/S/N)
Trial: 27206947
Drug: Lp(a)-lowering therapies
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lp(a)-lowering therapies (systematic review)
Trial: 18929475
Drug: Camphor-Crataegus berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camphor-Crataegus berry extract combination (Korodin(®))
Trial: 11849200
Drug: First antihypertensive
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First antihypertensive treatment
Trial: 11849200
Drug: Second antihypertensive
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second antihypertensive treatment
Trial: 11849200
Drug: Third antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third antihypertensive treatment
Trial: 11849200
Drug: Gender influence
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender influence on treatment willingness
Trial: 11081784
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (8 mg once daily, increased to 16 mg after 4 weeks)
Trial: 11081784
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg once daily, increased to 100 mg after 4 weeks)
Trial: 3936081
Drug: Citalopram 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 25 mg
Trial: 3936081
Drug: Citalopram 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 50 mg
Trial: 22750851
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Personal Standards perfectionism and Evaluative Concerns perfectionism
Trial: 22750851
Drug: Perfectionist conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfectionist conditions (High Personal Standards and Combination of Personal Standards and Evaluative Concerns)